The use of targeted agents in first and subsequent lines of therapy is improving outcomes in patients with mutated lung cancer progressing on standard chemotherapy, but a biomarker- or precision-guided approach is needed

Further studies are needed to understand the position of the fourth-generation agents NVL-520 and NVL-655 in the treatment paradigm of mutated lung cancer 

Neoadjuvant immunotherapy combinations were associated with high long-term survival rates and were superior to adjuvant nivolumab in patients with resectable melanoma, according to a phase III study and analysis of pooled studies 

High rates of pathological complete response were reported with neoadjuvant datopotamab deruxtecan plus durvalumab in patients with specific subtypes of breast cancer and at high risk of recurrence

Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation 

Final analysis of the KEYNOTE-811 trial reports positive findings when adding pembrolizumab to trastuzumab and chemotherapy in treatment-naïve patients

Final late-phase trial results show that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients  

New positive findings from research in advanced or metastatic breast cancer support the use of these agents in wider patient populations

The fields of metastatic pancreatic NETs and advanced and low proliferative grade 3 disease tumours move forward

Results from early-phase studies reveal potential for a new cancer vaccine and adaptive immunotherapy